1. Academic Validation
  2. Kynurenine-3-monooxygenase: A new direction for the treatment in different diseases

Kynurenine-3-monooxygenase: A new direction for the treatment in different diseases

  • Food Sci Nutr. 2020 Jan 20;8(2):711-719. doi: 10.1002/fsn3.1418.
Yifei Lu 1 Mingmei Shao 1 Tao Wu 1
Affiliations

Affiliation

  • 1 Institute of Interdisciplinary Integrative Medicine Research Shanghai University of Traditional Chinese Medicine Shanghai China.
Abstract

Kynurenine-3-monooxygenase (KMO) is an Enzyme that relies on nicotinamide adenine dinucleotide phosphate (NADP), a key site in the kynurenine pathway (KP), which has great effects on neurological diseases, Cancer, and peripheral inflammation. This review mainly pay attention to the research of KMO mechanism for the treatment of different diseases, and hopes to provide assistance for clinical and drug use. KMO controlling the chief division of the KP, which directly controls downstream product quinolinic acid (QUIN) and indirectly controls kynurenic acid (KYNA), plays an important role in many diseases, especially neurological diseases.

Keywords

KMO; kynurenic acid; kynurenine pathway; mechanism; quinolinic acid.

Figures